Program
tedizolid phosphate
Also written as “TR-701 FA”, “Tedizolid phosphate” and “TR-701 FA 200 mg”.
Its studies are mostly in Skin Diseases, Bacterial · Bacterial Infections · Gram-Positive Bacterial Infections · Pneumonia · Skin Diseases, Infectious, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Merck | 250 open or running | phase 3since Jul 23, 2010 | Apr 23, 2008 | none ahead |
| Bayer | 10 open or running | phase 3since Oct 18, 2013 | Oct 18, 2013 | none ahead |
| Dong-A ST | 10 open or running | phase 1since Mar 24, 2014 | Mar 24, 2014 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 13 studies since Apr 23, 2008.
- Dec 19, 2011Phase 1 study in Healthy SubjectsMerck · NCT01496677 · 28 enrolled · United States
- Jan 24, 2012Phase 2 study in CellulitisMerck · NCT01519778 · 200 enrolled · United States
- Feb 21, 2012Phase 1 study in Healthy VolunteersMerck · NCT01539473 · 30 enrolled · United States
- Apr 11, 2012Phase 1 study in Healthy SubjectsMerck · NCT01577459 · 18 enrolled · United States
- Jun 6, 2012Phase 1 study in Healthy SubjectsMerck · NCT01623401 · 72 enrolled · United States
- Oct 18, 2013Bayer's first study: phase 3 study in Skin Diseases, InfectiousNew to BayerBayer · NCT01967225 · 125 enrolled · Japan
- Dec 18, 2013Phase 3 study in PneumoniaMerck · NCT02019420 · 726 enrolled
- Mar 24, 2014Dong-A ST's first study: phase 1 study in HealthyNew to Dong-A STDong-A ST · NCT02097043 · 31 enrolled · Korea, Republic of
- Oct 9, 2014Phase 3 study in Skin Diseases, InfectiousMerck · NCT02276482 · 120 enrolled
- Jun 17, 2015Phase 1 study in Skin Diseases, BacterialMerck · NCT02477514 · 18 enrolled
- Apr 1, 2016Phase 1 study in Gram-Positive Bacterial InfectionsMerck · NCT02750761 · 32 enrolled
- Jun 1, 2017Phase 3 study in Acute Bacterial Skin and Skin Structure InfectionsMerck · NCT03176134 · 100 enrolled · United States, Brazil, Bulgaria and more
- Jul 12, 2017Phase 1 study in Gram-Positive InfectionsMerck · NCT03217565 · 47 enrolled · United States, Bulgaria, Colombia and more
- Dec 10, 2024Phase 1 study in HealthyMerck · NCT06733688 · 36 enrolled · United States
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“Bacterial 70S ribosome inhibitor”ChEMBL 37, by rule
Studies
All 27 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06733688Healthy · United States | 1 | Completed | Merck | Apr 15, 2022 | 36 |
| NCT03217565Gram-Positive Infections · United States, Bulgaria, Colombia and more | 1 | Completed | Merck | Mar 18, 2023 | 47 |
| NCT03176134Acute Bacterial Skin and Skin Structure Infections · United States, Brazil, Bulgaria and more | 3 | Completed | Merck | Jul 6, 2023 | 100 |
| NCT02750761Gram-Positive Bacterial Infections | 1 | Completed | Merck | Dec 16, 2018 | 32 |
| NCT02477514Skin Diseases, Bacterial | 1 | Completed | Merck | Aug 2015 | 18 |
| NCT02276482Skin Diseases, Infectious | 3 | Completed | Merck | Sep 17, 2018 | 120 |
| NCT02097043Healthy · Korea, Republic of | 1 | Completed | Dong-A ST | May 2014 | 31 |
| NCT02019420Pneumonia | 3 | Completed | Merck | Jun 22, 2018 | 726 |
| NCT01967225Skin Diseases, Infectious · Japan | 3 | Completed | Bayer | Oct 28, 2016 | 125 |
| NCT01623401Healthy Subjects · United States | 1 | Completed | Merck | Aug 24, 2012 | 72 |
| NCT01577459Healthy Subjects · United States | 1 | Completed | Merck | Jun 15, 2012 | 18 |
| NCT01539473Healthy Volunteers · United States | 1 | Completed | Merck | May 2012 | 30 |
| NCT01519778Cellulitis · United States | 2 | Completed | Merck | Aug 27, 2012 | 200 |
| NCT01496677Healthy Subjects · United States | 1 | Completed | Merck | Feb 28, 2012 | 28 |
| NCT01461460Healthy Volunteer · United States | 1 | Completed | Merck | Dec 23, 2011 | 48 |
| NCT01452828Renal Insufficiency · United States | 1 | Completed | Merck | Mar 2012 | 24 |
| NCT01421511Skin and Subcutaneous Tissue Bacterial Infections · United States, Argentina, Australia and more | 3 | Completed | Merck | Jan 10, 2013 | 666 |
| NCT01431833Hepatic Impairment · United States | 1 | Completed | Merck | May 2012 | 32 |
| NCT01271998Bacterial Infections · United States | 1 | Completed | Merck | Jan 3, 2011 | 20 |
| NCT01170221Skin and Subcutaneous Tissue Bacterial Infections · United States, Argentina, Brazil and more | 3 | Completed | Merck | Sep 30, 2011 | 667 |
| NCT01156077Bacterial Infections | 1 | Completed | Merck | Sep 24, 2011 | 20 |
| NCT00983255Bacterial Infections · United States | 1 | Completed | Merck | Jan 2010 | 90 |
| NCT00876655Healthy · United States | 1 | Completed | Merck | Mar 2009 | 12 |
| NCT00761215Skin Diseases, Infectious · United States | 2 | Completed | Merck | Feb 24, 2009 | 192 |
| NCT00671814Healthy Subjects · United States | 1 | Completed | Merck | Jun 6, 2008 | 80 |
| NCT00671359Healthy · United States | 1 | Completed | Merck | May 15, 2008 | 12 |
| NCT00666601Healthy · United States | 1 | Completed | Merck | Aug 12, 2008 | 15 |
How it is read
Names in the registry
- “TR-701 FA”, 9 entries
- “Tedizolid phosphate”, 2 entries
- “TR-701 FA 200 mg”, 2 entries
- “IV Tedizolid Phosphate”, 1 entry
- “Tedizolid Phosphate Oral Formulation 1 (Reference)”, 1 entry
Codes read as this program: TR701.
Conditions, from the studies’ own filings
- Skin Diseases, Bacterial, 3 studies
- Bacterial Infections, 3 studies
- Gram-Positive Bacterial Infections, 1 study
- Pneumonia, 1 study
- Skin Diseases, Infectious, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.